Agenus (NASDAQ:AGEN) Earns Neutral Rating from HC Wainwright

Agenus (NASDAQ:AGEN)‘s stock had its “neutral” rating reiterated by analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $7.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 100.57% from the company’s previous close.

Other analysts have also issued research reports about the company. StockNews.com lowered Agenus from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. B. Riley dropped their target price on Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $10.00.

Agenus Price Performance

AGEN stock opened at $3.49 on Friday. The business has a 50 day simple moving average of $4.25 and a 200-day simple moving average of $8.16. The firm has a market capitalization of $81.88 million, a PE ratio of -0.31 and a beta of 1.39. Agenus has a 1 year low of $2.50 and a 1 year high of $19.69.

Hedge Funds Weigh In On Agenus

A number of institutional investors have recently made changes to their positions in the business. Barclays PLC grew its stake in Agenus by 295.3% during the 3rd quarter. Barclays PLC now owns 27,813 shares of the biotechnology company’s stock worth $152,000 after buying an additional 20,777 shares during the last quarter. Geode Capital Management LLC grew its holdings in Agenus by 7.1% during the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock worth $2,648,000 after acquiring an additional 32,016 shares during the period. EP Wealth Advisors LLC bought a new stake in shares of Agenus in the 3rd quarter worth approximately $55,000. State Street Corp lifted its position in shares of Agenus by 2.1% during the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock valued at $2,563,000 after acquiring an additional 9,731 shares during the last quarter. Finally, Point72 DIFC Ltd increased its stake in Agenus by 380.0% in the 3rd quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 11,542 shares in the last quarter. 61.46% of the stock is owned by institutional investors and hedge funds.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.